Duligotuzumab

Duligotuzumab (INN) is a humanized IgG1 monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to HER3.[1] It is in development by Roche. Clinical development for head and neck cancer and colorectal cancer have been discontinued, but phase I trials in combination with cobimetinib are evaluating safety for treatment of solid tumors.[2]

Duligotuzumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetHER3
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.